Complications after salvage radical prostatectomy: vesicourethral anastomosis leaks and possible prevention

Raisa S. Pompe¹, Derya Tilki¹²

¹Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ²Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Correspondence to: Derya Tilki, MD. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Email: d.tilki@uke.de.

Provenance: This is a Guest Editorial commissioned by Editorial Board Member Dr. Xiongbing Zu, MD, PhD (Department of Urology, Xiangya Hospital, Central South University, Changsha, China).

Comment on: Ogaya-Pinies G, Kadakia Y, Palayapalayam-Ganapathi H, et al. Use of Scaffolding Tissue Biografts To Bolster Vesicourethral Anastomosis During Salvage Robot-assisted Prostatectomy Reduces Leak Rates and Catheter Times. Eur Urol 2016. [Epub ahead of print].

Next to radical prostatectomy (RP), definitive radiotherapy (RT) represents one of the most common treatment modalities for localized prostate cancer (PCa). Yet, 22%–63% of RT patients will develop biochemical recurrence (BCR) after primary treatment (1,2). While RT is considered a valid second line option after surgical failure, the majority of radiation-recurrent patients will receive androgen deprivation therapy (ADT) (1,2). However, in the setting of local recurrence, standard management with ADT might result in overtreatment without curative intent that causes several life-lasting side effects and harms Quality of life (QoL) (3). In consequence, more tailored options that balance the relation of cancer control while optimizing QoL and reducing lasting side effects are needed. In this context, the role of salvage radical prostatectomy (SRP) has evolved over the last decade. A recent review by Chade et al. demonstrated safety and improvement of different outcomes after SRP (4). Their review included publications on SRP between 1980 and 2011 and analyzed the trend over time for complications, pathological, oncological and functional results. The authors revealed improved pathological outcomes showing for example decreased rates of positive surgical margins (PSM) ranging from 43–70% in earlier to 0–36% in more recent reports. Similarly, more recent reports showed higher rates of organ-confined disease compared to earlier series (44–73% vs. 22–53%). Moreover, the authors postulated durable oncological outcomes with 5- and 10-year biochemical recurrence-free survival (BFS) rates ranging between 47–82% and 28–53% (4). Most recently, Marra et al. presented pathological and oncological outcomes among 243 SRP patients in a multicenter setting. Here, the authors found PSM in 37% and extra-prostatic extension in 49% of the patients. During the follow-up period (median 37 months), 44% developed BCR (5).

To improve cancer control, patient selection for SRP is essential. In this context, Mandel et al. showed considerably higher BFS rates in SRP patients that met the EAU guideline criteria for SRP (6). The study included 55 SRP-patients, 32 who met vs. 23 who did not meet EAU criteria and reported 5-year BFS rates of 73.9% vs. 11.6%.

Nevertheless, SRP remains a challenging procedure that can lead to severe complications (4). Due to radiation induced tissue adhesions and vessel injuries, rectal lesions and hemorrhages are the surgeon’s major concerns (4,7). One other frequently observed complication is an anastomotic leak after vesicourethral anastomosis (VUA) (8,9). The subsequent urine leakage results in longer catheterization and might predispose to urethral strictures and bladder neck contractures (10). Although the latter relation has not been conclusively investigated, several authors support the theory that anastomotic leaks may lead to persistent inflammatory which in consequence can restrict the wound healing process and subsequently cause contractures or stenosis (10).

Traditionally, SRP was performed using an open surgical
One of the largest series on sRALP was published in 2014 by Yuh et al. In their report, the authors retrospectively analyzed 51 patients that underwent sRALP between 2004 and 2012 and found anastomotic leaks in 18% of patients (8). All patients underwent cystography two weeks after sRALP. In case of urine leakage, the transurethral catheter was left in situ for another week. Median catheterization time was 15 days and in two cases following bladder neck contracture was attributed to the anastomotic leaks. With 34%, Bates et al. observed an even higher rate of anastomotic leaks in 53 patients undergoing sRALP compared to 33 primary RALP controls between 2008 and 2014 (12). Cystographic urinary leakage was found in 18 (34%) sRALP patients compared to three (6%) primary RALP patients. No information on urethral strictures or bladder neck contractures was available in their series. Similarly, Eandi et al. reported on 18 sRALP patients between 2004 and 2008 (9). Cystography was performed on day 10 to 14 and revealed anastomotic leaks in six patients (33%). Overall, three (17%) urethral strictures were registered. All of them occurred in patients that had previous anastomotic leaks. In consequence, novel techniques to improve VUA and prevent anastomotic leaks are of high interest.

In an article for the Surgery in Motion section of European Urology, Ogaya-Pinies and colleagues described feasibility, safety and functional outcomes for the use of a scaffolding tissue graft to prevent VUA rupture after salvage RALP (15). In 15 sRALP patients, a single surgeon incorporated porcine urinary bladder extracellular matrix (UB-ECM) into the posterior part of the VUA base and distal bladder neck. To this aim, the UB-ECM scaffold was cut as a triangle with a rectangular piece attached to the base and placed with the tip facing the bladder neck and the rectangular part close to the urethra. In the next step, the scaffold was sutured to the Denonvilliers’ fascia and after VUA, the rectangular part was wrapped around the anastomosis. These 15 procedures (group I) were 1:3:3 matched to 45 control sRALP without UB-ECM implantation (group II) and 45 primary RALP controls (group III). On day ten, all patients underwent control cystography. VUA rupture was defined as a contrast leak of ≥2 cm. Median follow-up was 12 months. The authors found radiologic disruption of the VUA in one of the patients in group I compared to 16 patients in group II and none in group III (P=0.0001). Accordingly, the median catheterization time differed between the three groups with 10.5 days in group I, 17.4 days in group II and 6.3 days in group III. However, 12-month urinary continence rates, defined as pad-free status, were similar among group I and II and significantly higher in group III (53% vs. 49% vs. 98%). During the follow-up, no major complications, bladder neck contractures or urethral strictures were reported among all 105 patients. The authors postulated that incorporation of an UB-ECM scaffold in the VUA is a promising method to reduce anastomotic leaks. With this report the authors investigated an important problem after sRALP and presented an innovative technique. Although incorporation of the scaffold did not result in better long-term UC rates, the rate of anastomotic leaks and catheterization time were significantly reduced. Especially longer catheterization may result in considerable patient discomfort and can cause several complications such as urinary tract infections (16,17). Furthermore, it is of note, that prolonged catheterization might be associated with worse short-term UC (18). For example, Palisaar et al. showed an adverse effect of prolonged catheterization (≤7 vs. 8–15 vs. >15 days) on six-week UC, defined as ≤1 pad/24 hours in 2998 patients who underwent open RP or RALP (18).

The used acellular ECM scaffold is derived from the basement membrane and lamina propria of porcine urinary bladder. By now, the underlying mechanisms for the constructive remodeling process that promotes differentiation to site-specific tissue are not completely understood. Despite induction of growth factors, degradation products of ECM are assumed to be responsible for subsequent recruitment and proliferation of suitable cell types (19).

As the authors stated, no previous studies examined ECM scaffold in the context of urologic surgery. However, utilization of ECM can be found in numerous preclinical and clinical applications such as wound management, corneal reconstructions or esophagojejunal anastomosis after gastrectomy showing promising results (20-22).

In summary, the authors provide a novel approach to solve the problem of anastomotic leaks especially in the context of surgically challenging sRALP. Further studies, ideally in a randomized setting with higher patient numbers and more follow-up, are needed to verify these first results.

**Acknowledgements**

None.
Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Agarwal PK, Sadetsky N, Konety BR, et al. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008;112:307-14.
2. Shipley WU, Thames HD, Sandler HM, et al. Radiation Therapy for Clinically Localized Prostate Cancer: A Multi-institutional Pooled Analysis. JAMA 1999;281:1598-604.
3. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111:543-8.
4. Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61:961-71.
5. Marra G, Gontero P, Alessio P, et al. Oncological Outcomes of Salvage Radical Prostatectomy: a multicentre series of 243 patients. The Journal of Urology, Supplement, May 2017.
6. Mandel P, Steuber T, Ahyai S, et al. Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. BJU Int 2016;117:55-61.
7. Heidenreich A, Richter S, Thuer D, et al. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. European urology 2010;57:437-43.
8. Yuh B, Ruel N, Muldrew S, et al. Complications and outcomes of salvage robot-assisted radical prostatectomy: a single-institution experience. BJU Int 2014;113:769-76.
9. Eandi JA, Link BA, Nelson RA, et al. Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. J Urol 2010;183:133-7.
10. Tyririzis SI, Katafigiotis I, Constantinides CA. All you need to know about urethresovesical anastomotic urinary leakage following radical prostatectomy. J Urol 2012;188:369-76.
11. Jamal K, Challacombe B, Elhage O, et al. Successful salvage robotic-assisted radical prostatectomy after external beam radiotherapy failure. Urology 2008;72:1356-8.
12. Bates AS, Samavedi S, Kumar A, et al. Salvage robot assisted radical prostatectomy: A propensity matched study of perioperative, oncological and functional outcomes. Eur J Surg Oncol 2015;41:1540-6.
13. Kaffenberger SD, Keegan KA, Bansal NK, et al. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol 2013;189:507-13.
14. Gontero P, Marra G, Alessio P, et al. Functional Outcomes and Complications of a Multicentre Series of Open versus Robot-assisted Salvage Radical Prostatectomy. Eur Urol Suppl March 2017.
15. Ogaya-Pinies G, Kadakia Y, Palayapalayam-Ganapathi H, et al. Use of Scaffolding Tissue Biografts To Bolster Vesicourethral Anastomosis During Salvage Robot-assisted Prostatectomy Reduces Leak Rates and Catheter Times. European urology 2016.
16. Lepor H, Nieder AM, Fraimann MC. Early removal of the urinary catheter after radical prostatectomy is both feasible and desirable. Urology 2001;58:425-9.
17. Sedor J, Mulholland SG. Hospital-acquired urinary tract infections associated with the indwelling catheter. Urol Clin North Am 1999;26:821-8.
18. Palisaar JR, Roghmann F, Brock M, et al. Predictors of short-term recovery of urinary continence after radical prostatectomy. World J Urol 2015;33:771-9.
19. Reing JE, Zhang L, Myers-Irvin J, et al. Degradation products of extracellular matrix affect cell migration and proliferation. Tissue Eng Part A 2009;15:605-14.
20. Kimmel H, Rahn M, Gilbert TW. The Clinical Effectiveness in Wound Healing With Extracellular Matrix Derived From Porcine Urinary Bladder Matrix: A Case Series on Severe Chronic Wounds. J Am Col Certif Wound Spec 2010;2:55-9.
21. Afaneh C, Abelson J, Schattner M, et al. Esophageal reinforcement with an extracellular scaffold during total gastrectomy for gastric cancer. Ann Surg Oncol 2015;22:1252-7.
22. Ballard O, Poinsard AS, Famose F, et al. Use of a porcine urinary bladder acellular matrix for corneal reconstruction in dogs and cats. Vet Ophthalmol 2016;19:454-63.

Cite this article as: Pompe RS, Tilki D. Complications after salvage radical prostatectomy: vesicourethral anastomosis leaks and possible prevention. Transl Androl Urol 2017;6(5):994-996. doi: 10.21037/tau.2017.03.66